OC4
Fracture-targeted Anabolics for Treatment of Osteogenesis Imperfecta Fractures

Stewart Low[1], Jeffery Nielsen[1], Xinlan Lu[1], Arden Shen[2], Mini Thomas[1], Karen Smith[1]
[1]Quince Therapeutics Inc, West Lafayette, USA. [2]Purdue University, West Lafayette, USA

Dr Karen Smith MD, PhD, MBA, LLM
Chief Medical Officer
Quince Therapeutics

QUINCE THERAPEUTICS

Forward-looking statements

Statements in this presentation contain “forward-looking statements” that are subject to substantial risks and uncertainties. Forward-looking statements contained in this presentation may be identified by the use of words such as “expect,” “will,” “estimate,” “project,” “potential,” “positioned,” "advancing," "planned," "progression," "targeting," "allow," "identify," "concluding," "leader," "progress," "underway," "goal,“ or other similar words. Examples of forward-looking statements include, among others, clinical development and strategic development path for NOV004; cash runway and the ability to fund clinical development milestones; the company’s plans to pursue the strategic expansion of its development pipeline, its intent to out-license its legacy neuroscience and antiviral assets, the strategic growth plan, the FDA and clinical development plans and timeline, prospects, and milestone expectations; the timing and success of the company’s clinical trials and related data, including plans and the ability to initiate, conduct and/or complete the Phase 1 clinical studies for NOV004; the timing of announcements and updates relating to its clinical trials and related data; the potential therapeutic benefits, safety, and efficacy of the company’s product candidate and discovery pipeline; and statements about its ability to obtain, and the timing relating to, further development and/or out-licensing of its legacy neuroscience and antiviral assets, regulatory submissions, and related response and decisions. Forward-looking statements are based on Quince’s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict and could cause actual results to differ materially from what the company expects. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, but are not limited to, the risks and uncertainties described in the section titled “Risk Factors” in the company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 1, 2022, its Quarterly Report on Form 10-Q filed with the SEC on May 10, 2022, and other reports as filed with the SEC. Forward-looking statements contained in this presentation are made as of this date, and Quince Therapeutics undertakes no duty to update such information except as required under applicable law.

Highly differentiated precision bone disease platform

Designed to systemically deliver targeted small molecules, peptides or large molecules directly to the site of fracture or disease





NOV004 discovered at Low lab at Purdue University

Therapeutic Agent

- Abaloparatide payload
- Parathyroid hormone related protein analog
- Increases bone density and approved for osteoporosis

Biological Linker

- Links targeting ligand to abaloparatide payload
- Short sequence of amino acids
- Allows payload to interact with receptors on nearby cells

Targeting Ligand

- Concentrates abaloparatide payload at fracture site
- Sequence of negatively charged glutamic acid
- Binds to hydroxyapatite with high affinity at site of bone trauma



Uniquely engineered structure delivers anabolic that accelerates repair directly to fracture site

Precise drug targeting increases efficacy



Fractures / Grafts	Osteomyelitis	Bone Cancer / Bone Metastases

NOV004 concentrated drug increases half-life

Drug and Site		Half-Life (Hours)
Non-targeted Drug	Contralateral Femur	1.6
	Fractured Femur	8.8
NOV004	Contralateral Femur	5.7
	Fractured Femur	**66.4**

NOV004 AUC is 10x that of non-targeted drug at the fracture site



NOV004 rapidly builds dense and strong bone







New Bone *Dense Bone* *Strong Bone*

NOV004 improves function following fracture





NOV004 treated mice move earlier, farther, and faster following femoral fractures

Fracture healing in osteogenesis imperfecta as lead indication

- IND enabling studies completed – Pre-IND targeted for 4Q2022
- Phase 1 studies in healthy normal and adult fracture populations commencing 2023
- Ph2a study in OI patient population in development
  - Preclinical data supports uptake of NOV004 as a hydroxyapatite targeted bone therapy
  - Payload is an anabolic peptide
- Preclinical results in OI Type 3 vs. saline control:
  - 2x improvement in bone volume/total volume
  - 3x improvement in max load

Working with experts in the field of OI to help shape clinical development plans

Osteogenesis imperfecta in fracture repair

OI Type I

Fracture Mineralization



Mechanical Strength



OI Type III

Fracture Mineralization



Mechanical Strength



Potential osteogenesis imperfecta fracture prevention

Whole-body drug distribution

Healthy skeleton



OI III skeleton



Strengthening healthy OI Type I femurs



QUINCE THERAPEUTICS

Contacts:

Stew Low, PhD
Head, Discovery
slow@quincetx.com

Maureen Roden
Vice President, Clinical Development
mroden@quincetx.com

Mark Schneider, MD MPH
Sr. Director, Clinical Devt and Medical Affairs
mschneider@quincetx.com

Karen Smith, MD, PhD
Chief Medical Officer
ksmith@quincetx.com